We are live on ! Find out more
CSTL icon

Castle Biosciences
CSTL

67 hedge funds and large institutions have $176M invested in Castle Biosciences in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 8

133% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 12

99% more capital invested

Capital invested by funds: $88.1M → $176M (+$87.5M)

18% more funds holding

Funds holding: 57 → 67 (+10)

1.4% more ownership

Funds ownership: 28.52% → 29.93% (+1.4%)

Holders
67
Holders Change
+10
Holders Change %
+17.54%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
23
Increased
28
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.58M
2
PCM
Portolan Capital Management
Massachusetts
+$4.42M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$4.36M
4
WA
Wasatch Advisors
Utah
+$2.47M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.14M

Top Sellers

Rank Fund Capital Flow
1
NAM
Nexpoint Asset Management
Texas
-$7.92M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$4.07M
3
Millennium Management
Millennium Management
New York
-$2.81M
4
RI
RTW Investments
New York
-$2.79M
5
PVI
Pura Vida Investments
New York
-$2.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
CMBA
51
C.M. Bidwell & Associates
Hawaii
$74K +$52.6K +2,150 New
Citigroup
52
Citigroup
New York
$71K +$46.8K +1,915 +1,175%
Victory Capital Management
53
Victory Capital Management
Texas
$69K -$17.2K -702 -26%
JP Morgan Chase
54
JP Morgan Chase
New York
$58K +$11.6K +476 +39%
Deutsche Bank
55
Deutsche Bank
Germany
$44K +$7.12K +291 +28%
GRP
56
Global Retirement Partners
California
$38K +$26.9K +1,101 New
SO
57
STRS Ohio
Ohio
$34K – – –
Legal & General Group
58
Legal & General Group
United Kingdom
$24K +$2.76K +113 +20%
AS
59
Altshuler Shaham
Israel
$17K +$11.8K +481 New
Bank of Montreal
60
Bank of Montreal
Ontario, Canada
$17K +$11.8K +484 New
TI
61
tru Independence
Oregon
$14K +$11.1K +455 New
AIP
62
Ameritas Investment Partners
Nebraska
$11K – – –
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
$9K +$6.7K +274 New
PAM
64
Panagora Asset Management
Massachusetts
$7K +$4.87K +199 New
Daiwa Securities Group
65
Daiwa Securities Group
Japan
$3K +$2.35K +96 New
TWA
66
TCI Wealth Advisors
Arizona
$1K +$513 +21 New
Millennium Management
67
Millennium Management
New York
– -$2.81M -155,538 Closed
PVI
68
Pura Vida Investments
New York
– -$2.38M -131,718 Closed
DM
69
Deerfield Management
New York
– -$1.67M -92,477 Closed
LCM
70
Laurion Capital Management
New York
– -$542K -29,986 Closed
DIM
71
DC Investments Management
Virginia
– -$507K -28,038 Closed
MWNA
72
Marshall Wace North America
New York
– -$444K -24,524 Closed
LCM
73
Landscape Capital Management
New Jersey
– -$256K -14,138 Closed
CCA
74
Catalyst Capital Advisors
New York
– -$5K -300 Closed
GWS
75
Glassman Wealth Services
Virginia
– +$220 +9 New
1 2
3

CSTL Hedge Fund Activity: Q4 2019 in Review

67 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2019, worth a combined $176M — up 99% from $88.1M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CSTL positions and 8 closed out — a net gain of 15 holders — while 28 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $5.58M. The largest seller was Nexpoint Asset Management, cutting an estimated $7.92M.

  • 67 institutional investors held Castle Biosciences (CSTL) as of Q4 2019, up from 57 in Q3 2019.
  • Funds reported $176M of Castle Biosciences stock for Q4 2019, up 99% quarter-over-quarter.
  • 23 funds opened new Castle Biosciences positions in Q4 2019 and 8 closed out, a net change of +15 holders.
  • The largest Castle Biosciences buyer in Q4 2019 was BlackRock, an estimated $5.58M added.
  • The largest Castle Biosciences seller in Q4 2019 was Nexpoint Asset Management, an estimated $7.92M sold.

Based on aggregated 13F filings for Q4 2019.